<SEC-DOCUMENT>0001610717-25-000289.txt : 20250718
<SEC-HEADER>0001610717-25-000289.hdr.sgml : 20250718
<ACCEPTANCE-DATETIME>20250718171405
ACCESSION NUMBER:		0001610717-25-000289
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20250716
FILED AS OF DATE:		20250718
DATE AS OF CHANGE:		20250718

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Symons Julian A.
		CENTRAL INDEX KEY:			0001824727
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39617
		FILM NUMBER:		251135172

	MAIL ADDRESS:	
		STREET 1:		C/O ALIGOS THERAPEUTICS, INC.
		STREET 2:		ONE CORPORATE DRIVE, 2ND FLOOR
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Aligos Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001799448
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		ONE CORPORATE DR., 2ND FLOOR
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		(800) 466-6059

	MAIL ADDRESS:	
		STREET 1:		ONE CORPORATE DR., 2ND FLOOR
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>form4.xml
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0508</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2025-07-16</periodOfReport>

    <issuer>
        <issuerCik>0001799448</issuerCik>
        <issuerName>Aligos Therapeutics, Inc.</issuerName>
        <issuerTradingSymbol>ALGS</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001824727</rptOwnerCik>
            <rptOwnerName>Symons Julian A.</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O ALIGOS THERAPEUTICS, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>1 CORPORATE DRIVE, 2ND FLOOR</rptOwnerStreet2>
            <rptOwnerCity>SOUTH SAN FRANCISCO</rptOwnerCity>
            <rptOwnerState>CA</rptOwnerState>
            <rptOwnerZipCode>94080</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isOfficer>true</isOfficer>
            <officerTitle>See Remarks</officerTitle>
        </reportingOwnerRelationship>
    </reportingOwner>

    <aff10b5One>false</aff10b5One>

    <derivativeTable>
        <derivativeTransaction>
            <securityTitle>
                <value>Stock Option (Right to Buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>8.68</value>
            </conversionOrExercisePrice>
            <transactionDate>
                <value>2025-07-16</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>16000</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <exerciseDate>
                <footnoteId id="F1"/>
            </exerciseDate>
            <expirationDate>
                <value>2035-07-16</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>16000</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>16000</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeTransaction>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from July 16, 2025 (the &quot;Vesting Commencement Date&quot;), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.</footnote>
    </footnotes>

    <remarks>Executive Vice President, Chief Scientific Officer</remarks>

    <ownerSignature>
        <signatureName>/s/ Lesley Ann Calhoun, as attorney-in fact for Julian A. Symons</signatureName>
        <signatureDate>2025-07-18</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
